FibroBiologics receives Nasdaq delisting notice for bid price non-compliance; plans hearing and reverse split vote

FibroBiologics, Inc.

Nasdaq notified delisting on Dec 30, 2025, after 180-day cure period ended Dec 29 without compliance.
Company plans to request a hearing before the Nasdaq Hearings Panel to stay delisting.
Proxy filed Dec 29 seeking stockholder approval for reverse stock split (1-for-5 to 1-for-30).
No assurance of extension or successful regaining of compliance with $1.00 bid price rule.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.